Krystal Biotech KRYS
NASDAQ KRYS
$308.81 +2.31 (+0.75%)
At close: Nov 11, 2026 · 4:00 PM EST

Krystal Biotech (KRYS) Convertible Debt (2016)

Updated

Krystal Biotech's Convertible Debt was $1.15 million in Q4 2016.

Analysis

Krystal Biotech (KRYS) Convertible Debt (2016) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Krystal Biotech 9.08 Bn 5.67 Bn 119.79 Mn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2016 1.15 Mn
API Access

Krystal Biotech Convertible Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=convertible-debt&ticker=KRYS&period=max&api_key=YOUR_API_KEY